Cargando…
Recent Advances in Understanding and Mitigating Adipogenic and Metabolic Effects of Antipsychotic Drugs
Although offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has witnessed substantial re...
Autores principales: | Gohlke, Julia M., Dhurandhar, Emily J., Correll, Christoph U., Morrato, Elaine H., Newcomer, John W., Remington, Gary, Nasrallah, Henry A., Crystal, Stephen, Nicol, Ginger, Allison, David B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385013/ https://www.ncbi.nlm.nih.gov/pubmed/22754543 http://dx.doi.org/10.3389/fpsyt.2012.00062 |
Ejemplares similares
-
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018) -
Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes
por: Morrato, Elaine H., et al.
Publicado: (2009) -
Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021) -
Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021) -
Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease
por: Rodriguez, Guadalupe, et al.
Publicado: (2023)